Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. / Benn, Marianne; Tybjærg-Hansen, Anne; Stender, Stefan; Frikke-Schmidt, Ruth; Nordestgaard, Børge G; Benn, Marianne.

In: National Cancer Institute. Journal (Print), Vol. 103, No. 6, 16.03.2011, p. 508-19.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Benn, M, Tybjærg-Hansen, A, Stender, S, Frikke-Schmidt, R, Nordestgaard, BG & Benn, M 2011, 'Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study', National Cancer Institute. Journal (Print), vol. 103, no. 6, pp. 508-19. https://doi.org/10.1093/jnci/djr008, https://doi.org/10.1093/jnci/djr008

APA

Benn, M., Tybjærg-Hansen, A., Stender, S., Frikke-Schmidt, R., Nordestgaard, B. G., & Benn, M. (2011). Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. National Cancer Institute. Journal (Print), 103(6), 508-19. https://doi.org/10.1093/jnci/djr008, https://doi.org/10.1093/jnci/djr008

Vancouver

Benn M, Tybjærg-Hansen A, Stender S, Frikke-Schmidt R, Nordestgaard BG, Benn M. Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. National Cancer Institute. Journal (Print). 2011 Mar 16;103(6):508-19. https://doi.org/10.1093/jnci/djr008, https://doi.org/10.1093/jnci/djr008

Author

Benn, Marianne ; Tybjærg-Hansen, Anne ; Stender, Stefan ; Frikke-Schmidt, Ruth ; Nordestgaard, Børge G ; Benn, Marianne. / Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study. In: National Cancer Institute. Journal (Print). 2011 ; Vol. 103, No. 6. pp. 508-19.

Bibtex

@article{1f167b15a24e4c26baa1e9c6d1eef38f,
title = "Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study",
abstract = "Background Low plasma levels of low-density lipoprotein (LDL) cholesterol are associated with an increased risk of cancer, but whether this association is causal is unclear. Methods We studied 10¿613 participants in the Copenhagen City Heart Study (CCHS) and 59¿566 participants in the Copenhagen General Population Study, 6816 of whom had developed cancer by May 2009. Individuals were genotyped for PCSK9 R46L (rs11591147), ABCG8 D19H (rs11887534), and APOE R112C (rs429358) and R158C (rs7412) polymorphisms, all of which are associated with lifelong reduced plasma LDL cholesterol levels. Plasma LDL cholesterol was calculated using the Friedewald equation in samples in which the triglyceride level was less than 354 mg/dL and measured directly by colorimetry for samples with higher triglyceride levels. Risk of cancer was estimated prospectively using Cox proportional hazards regression analyses and cross-sectionally by logistic regression analyses. Causality was studied using instrumental variable analysis. All statistical tests were two-sided. Results In the CCHS, compared with plasma LDL cholesterol levels greater than the 66th percentile (>158 mg/dL), those lower than the 10th percentile (<87 mg/dL) were associated with a 43% increase (95% confidence interval [CI] = 15% to 79% increase) in the risk of cancer. The polymorphisms were associated with up to a 38% reduction (95% CI = 36% to 41% reduction) in LDL cholesterol levels but not with increased risk of cancer. The causal odds ratio for cancer for a 50% reduction in plasma LDL cholesterol level due to all the genotypes in both studies combined was 0.96 (95% CI = 0.87 to 1.05), whereas the hazard ratio of cancer for a 50% reduction in plasma LDL cholesterol level in the CCHS was 1.10 (95% CI = 1.01 to 1.21) (P for causal odds ratio vs observed hazard ratio = .03). Conclusion Low plasma LDL cholesterol levels were robustly associated with an increased risk of cancer, but genetically decreased LDL cholesterol was not. This finding suggests that low LDL cholesterol levels per se do not cause cancer. ",
author = "Marianne Benn and Anne Tybj{\ae}rg-Hansen and Stefan Stender and Ruth Frikke-Schmidt and Nordestgaard, {B{\o}rge G} and Marianne Benn",
year = "2011",
month = mar,
day = "16",
doi = "10.1093/jnci/djr008",
language = "English",
volume = "103",
pages = "508--19",
journal = "National Cancer Institute. Journal (Print)",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "6",

}

RIS

TY - JOUR

T1 - Low-density lipoprotein cholesterol and the risk of cancer: a mendelian randomization study

AU - Benn, Marianne

AU - Tybjærg-Hansen, Anne

AU - Stender, Stefan

AU - Frikke-Schmidt, Ruth

AU - Nordestgaard, Børge G

AU - Benn, Marianne

PY - 2011/3/16

Y1 - 2011/3/16

N2 - Background Low plasma levels of low-density lipoprotein (LDL) cholesterol are associated with an increased risk of cancer, but whether this association is causal is unclear. Methods We studied 10¿613 participants in the Copenhagen City Heart Study (CCHS) and 59¿566 participants in the Copenhagen General Population Study, 6816 of whom had developed cancer by May 2009. Individuals were genotyped for PCSK9 R46L (rs11591147), ABCG8 D19H (rs11887534), and APOE R112C (rs429358) and R158C (rs7412) polymorphisms, all of which are associated with lifelong reduced plasma LDL cholesterol levels. Plasma LDL cholesterol was calculated using the Friedewald equation in samples in which the triglyceride level was less than 354 mg/dL and measured directly by colorimetry for samples with higher triglyceride levels. Risk of cancer was estimated prospectively using Cox proportional hazards regression analyses and cross-sectionally by logistic regression analyses. Causality was studied using instrumental variable analysis. All statistical tests were two-sided. Results In the CCHS, compared with plasma LDL cholesterol levels greater than the 66th percentile (>158 mg/dL), those lower than the 10th percentile (<87 mg/dL) were associated with a 43% increase (95% confidence interval [CI] = 15% to 79% increase) in the risk of cancer. The polymorphisms were associated with up to a 38% reduction (95% CI = 36% to 41% reduction) in LDL cholesterol levels but not with increased risk of cancer. The causal odds ratio for cancer for a 50% reduction in plasma LDL cholesterol level due to all the genotypes in both studies combined was 0.96 (95% CI = 0.87 to 1.05), whereas the hazard ratio of cancer for a 50% reduction in plasma LDL cholesterol level in the CCHS was 1.10 (95% CI = 1.01 to 1.21) (P for causal odds ratio vs observed hazard ratio = .03). Conclusion Low plasma LDL cholesterol levels were robustly associated with an increased risk of cancer, but genetically decreased LDL cholesterol was not. This finding suggests that low LDL cholesterol levels per se do not cause cancer.

AB - Background Low plasma levels of low-density lipoprotein (LDL) cholesterol are associated with an increased risk of cancer, but whether this association is causal is unclear. Methods We studied 10¿613 participants in the Copenhagen City Heart Study (CCHS) and 59¿566 participants in the Copenhagen General Population Study, 6816 of whom had developed cancer by May 2009. Individuals were genotyped for PCSK9 R46L (rs11591147), ABCG8 D19H (rs11887534), and APOE R112C (rs429358) and R158C (rs7412) polymorphisms, all of which are associated with lifelong reduced plasma LDL cholesterol levels. Plasma LDL cholesterol was calculated using the Friedewald equation in samples in which the triglyceride level was less than 354 mg/dL and measured directly by colorimetry for samples with higher triglyceride levels. Risk of cancer was estimated prospectively using Cox proportional hazards regression analyses and cross-sectionally by logistic regression analyses. Causality was studied using instrumental variable analysis. All statistical tests were two-sided. Results In the CCHS, compared with plasma LDL cholesterol levels greater than the 66th percentile (>158 mg/dL), those lower than the 10th percentile (<87 mg/dL) were associated with a 43% increase (95% confidence interval [CI] = 15% to 79% increase) in the risk of cancer. The polymorphisms were associated with up to a 38% reduction (95% CI = 36% to 41% reduction) in LDL cholesterol levels but not with increased risk of cancer. The causal odds ratio for cancer for a 50% reduction in plasma LDL cholesterol level due to all the genotypes in both studies combined was 0.96 (95% CI = 0.87 to 1.05), whereas the hazard ratio of cancer for a 50% reduction in plasma LDL cholesterol level in the CCHS was 1.10 (95% CI = 1.01 to 1.21) (P for causal odds ratio vs observed hazard ratio = .03). Conclusion Low plasma LDL cholesterol levels were robustly associated with an increased risk of cancer, but genetically decreased LDL cholesterol was not. This finding suggests that low LDL cholesterol levels per se do not cause cancer.

U2 - 10.1093/jnci/djr008

DO - 10.1093/jnci/djr008

M3 - Journal article

C2 - 21285406

VL - 103

SP - 508

EP - 519

JO - National Cancer Institute. Journal (Print)

JF - National Cancer Institute. Journal (Print)

SN - 0027-8874

IS - 6

ER -

ID: 34151521